Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

trml

Short Term Investments

Last Annual Value

227.80M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Competitors Analysis of Short Term Investments

TRML · NASDAQ
CompanyShort Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
227.80M
54.1%0.2%N/A 
90.33M
-23.4%14.5%N/A
353.21M
104.3%50.8%N/A
363.73M
33.5%N/AN/A
235.82M
8.5%84.7%N/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
67.62M
7.0%-1.3%-9.0%
470.50M
-8.1%-7.0%N/A
259.14M
-2.8%2.9%12.3%
494.24M
39.1%33.1%N/A
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

Intrinsic Value
Current Price: $47.98